![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 06, 2010 8:44:24 AM
The benefits of aspirin are well-documented and more than five billion units of aspirin in all of its forms are sold in the U.S. each year. But because aspirin is linked with significant GI damage, it may be underutilized for both secondary prevention of cardiovascular disease as well as pain. “We are pleased to report that PA65020 reduces the incidence of upper GI damage compared to aspirin therapy,” said Dr. John Fort, Chief Medical Officer, POZEN. “These results are promising for the millions of people who could benefit from analgesic doses of aspirin therapy, but are at risk for upper GI damage from this treatment.”
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM